FDA Analyte-Specific Reagent Guidance Spells Out Small Lab Fundamentals
This article was originally published in The Gray Sheet
Executive Summary
Labeling and promotional material for Class I analyte-specific reagents may bear information clarifying that FDA does not require premarket review of the tests, according to the agency
You may also be interested in...
ODE/OIVD Fiscal 2003 Annual Report In Brief
Expedited PMAs review times: Average total review time for expedited PMA applications approved by the Office of Device Evaluation and the Office of In Vitro Diagnostic Device Evaluation & Safety in FY 2003 is 374.7 days, down from 471 days in FY 2002. However, the FY 2003 figure is still nearly 16 days greater than the average time for approved original PMAs. Elapsed FDA days averaged 304 for the six expedited submissions - 58 days longer than for the total PMA approval cohort mean. In November, FDA released a guidance on the expedited review program (1"The Gray Sheet" Dec. 1, 2003, p. 9)...
ODE/OIVD Fiscal 2003 Annual Report In Brief
Expedited PMAs review times: Average total review time for expedited PMA applications approved by the Office of Device Evaluation and the Office of In Vitro Diagnostic Device Evaluation & Safety in FY 2003 is 374.7 days, down from 471 days in FY 2002. However, the FY 2003 figure is still nearly 16 days greater than the average time for approved original PMAs. Elapsed FDA days averaged 304 for the six expedited submissions - 58 days longer than for the total PMA approval cohort mean. In November, FDA released a guidance on the expedited review program (1"The Gray Sheet" Dec. 1, 2003, p. 9)...
CDRH Reopens Analyte-Specific Reagent Rule, Expanding IVD Oversight
FDA will begin expanding oversight of homebrew in vitro diagnostics with a notice of proposed rulemaking on analyte-specific reagents in the coming weeks